GAMBACORTI PASSERINI CARLO

Posizione organizzativa:

Ruolo:

professore ordinario

Settore scientifico disciplinare:

MALATTIE DEL SANGUE (MED/15)

Afferenza:

E-mail:

Telefono:

0264488362
0264488057

Stanza:

U08, Piano: P04, Stanza: 4041
Via Cadore, 48 - 20900 MONZA

U8, Piano: IV, Stanza: 4-12
Via Cadore, 48 - 20900 MONZA

Hehlmann, R., Cortes, J., Zyczynski, T., Gambacorti-Passerini, C., Goldberg, S., Mauro, M., et al. (2019). Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. AMERICAN JOURNAL OF HEMATOLOGY, 94(1), 46-54. Dettaglio
Menotti, M., Ambrogio, C., Cheong, T., Pighi, C., Mota, I., Cassel, S., et al. (2019). Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. NATURE MEDICINE, 25(1), 130-140. Dettaglio
Michelozzi, I., Granata, V., DE PONTI, G., Alberti, G., Tomasoni, C., Antolini, L., et al. (2019). Acute myeloid leukaemia niche regulates response to L-asparaginase. BRITISH JOURNAL OF HAEMATOLOGY, 186(3), 420-430. Dettaglio
Magistroni, V., Mauri, M., D'Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., et al. (2019). De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. HAEMATOLOGICA. Dettaglio
Gambacorti Passerini, C., Orlov, S., Zhang, L., Braiteh, F., Huang, H., Esaki, T., et al. (2018). Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. AMERICAN JOURNAL OF HEMATOLOGY, 93(5), 607-614. Dettaglio

Futuri studenti